建议为老年人和高风险个人提供80%有效的RSV疫苗,2023-2024年冬季覆盖率低,为24%。 80% effective RSV vaccines recommended for older adults and high-risk individuals, coverage low at 24% in winter 2023-2024 season.

最近的研究证实,在预防60岁和60岁以上的成年人严重疾病方面,RSV疫苗有效率为80%,然而,在2023-2024年冬季,只有24%的人口接种了疫苗。 Recent research confirms that RSV vaccines are 80% effective in preventing severe illness among adults aged 60 and older, yet only 24% of this demographic received the vaccine during the 2023-2024 winter season. 美国 The U.S. 免疫做法咨询委员会现在建议为所有75岁以上的成年人和60岁以上的高危成年人接种疫苗。 Advisory Committee on Immunization Practices now recommends vaccination for all adults 75 and older and those 60 and older with high-risk conditions. 新的两用疫苗可以提供广泛的保护,突出表明需要提高公众对RSV和疫苗接种的认识。 New bivalent vaccines may offer extended protection, highlighting the need for improved public awareness about RSV and vaccination.